Mevalonate pathway: Role of bisphosphonates and statins

Acta Medica Mediterranea

Volumn 27, Issue 2, 2011, Pages 85-95

  Mansueto, Pasquale ^a   Vitale, Giustina ^a   Seidita, Aurelio ^a   Guarneri, Francesco Paolo ^a   Pepe, Ilenia ^a   Rinollo, Carmelina ^a   Di Rosa, Salvatore ^b   Rini, Giovambattista ^a   Cillari, Enrico ^b   Di Fede, Gaetana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera Ospedali Riuniti 'Villa Sofia Cervello'   (Italy)

Author keywords

Bisphosphonates; Cardiovascular disease; Mevalonate pathway; Osteoporosis; Statins

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; MEVALONIC ACID; PAMIDRONIC ACID; PRAVASTATIN; RISEDRONIC ACID; SIMVASTATIN; ZOLEDRONIC ACID;

ARTICLE; BONE METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY;

EID: 84865079145     PISSN: 03936384     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (135)

1. Whitney C, Warburton DE, Frohlich J, Chan SY, McKay H, Khan K. Are cardiovascular disease and osteoporosis directly linked? Sports Med 2004; 34: 779-807.
2. Baldini V, Mastropasqua M, Francucci CM, D'Erasmo E. Cardiovascular disease and osteoporosis. J Endocrinol Invest 2005; 28(10 Suppl): 69-72.
3. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose the). Watts N. Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 2002; 95: 578-82.
4. Ylitalo R. Bisphosphonates and atherosclerosis. Gen Pharmacol 2000; 35: 287-96.
5. Coons JC. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann Pharmacother 2002; 36: 326-30.
6. Moosmann B, Behl C. Selenoproteins, cholesterollowering drugs, and the consequences: revisiting of the mevalonate pathway. Trends Cardiovasc Med 2004; 14: 273-81.
7. Ericsson J, Dallner G. Distribution, biosynthesis, and function of mevalonate pathway lipids. Subcell Biochem 1993; 21: 229-72.
8. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
9. Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids 2004; 39: 293-309.
10. Edwards PA, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 1999; 68: 157-85.
11. Caruso ME, Jenna S, Beaulne S, Lee EH, Bergeron A, Chauve C, Roby P, Rual JF, Hill DE, Vidal M, Bosse R, Chevet E. Biochemical clustering of monomeric GTPases of the Ras superfamily. Mol Cell Proteomics 2005; 4: 936-44.
12. Lobell RB. Prenylation of Ras GTPase superfamily proteins and their function in immunobiology. Adv Immunol 1998; 68: 145-89.
13. Brunsveld L, Kuhlmann J, Alexandrov K, Wittinghofer A, Goody RS, Waldmann H. Lipidated ras and rab peptides and proteins--synthesis, structure, and function. Angew Chem Int Ed Engl 2006; 45: 6622-46.
14. Bernards A. Ras superfamily and interacting proteins database. Methods Enzymol 2005; 407: 1-9.
15. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. Curr Biol 2005; 15: R563-74.
16. Overbeck AF, Brtva TR, Cox AD, Graham SM, Huff SY, Khosravi-Far R, Quilliam LA, Solski PA, Der CJ. Guanine nucleotide exchange factors: activators of Ras superfamily proteins. Mol Reprod Dev 1995; 42: 468-76.
17. Debidda M, Williams DA, Zheng Y. Rac1 GTPase Regulates Cell Genomic Stability and Senescence. J Biol Chem 2006; 281: 385, 19-28.
18. Moorman JP, Luu D, Wickham J, Bobak DA, Hahn CS. A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival. Oncogene 1999; 18: 47-57.
19. Baugher PJ, Krishnamoorthy L, Price JE, Dharmawardhane SF. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells. Breast Cancer Res 2005; 7: R965-74.
20. Park EJ, Ji KA, Jeon SB, Choi WH, Han IO, You HJ, Kim JH, Jou I, Joe EH. Rac1 contributes to maximal activation of STAT1 and STAT3 in IFN-gamma-stimulated rat astrocytes. J Immunol 2004; 173: 5697-703.
21. Faruqi TR, Gomez D, Bustelo XR, Bar-Sagi D, Reich NC. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci USA 2001; 98: 9014-9.
22. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000; 290: 144-7.
23. Hammacher A, Ward LD, Weinstock J, Treutlein H, Yasukawa K, Simpson RJ. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci 1994; 3: 2280-93.
24. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-12.
25. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19: 2548-56.
26. Nakashima K, Taga T. gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. Semin Hematol 1998; 35: 210-21.
27. Song L, Schindler C. IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis 2004; 177: 43-51.
28. Haddy N, Sass C, Droesch S, Zaiou M, Siest G, Ponthieux A, Lambert D, Visvikis S. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-83.
29. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-70.
30. Terkeltaub R, Solan J, Barry M Jr, Santoro D, Bokoch GM. Role of the mevalonate pathway of isoprenoid synthesis in IL-8 generation by activated monocytic cells. J Leukoc Biol 1994; 55: 749-55.
31. Glowinska B, Urban M. Selected cytokines (Il-6, Il-8, Il-10, MCP-1, TNF-alpha) in children and adolescents with atherosclerosis risk factors: obesity, hypertension, diabetes. Wiad Lek 2003; 56: 109-16.
32. Jarstfer MB, Zhang DL, Poulter CD. Recombinant squalene synthase. Synthesis of non-head-to-tail isoprenoids in the absence of NADPH. J Am Chem Soc 2002; 124: 8834-45.
33. Bokoch GM, Zhao T. Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal 2006; 8: 1533-48.
34. Chapurlat RD, Delmas PD. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006; 2: 211-9.
35. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006; 1068: 367-401.
36. Rendina D, De Filippo G, Mossetti G. Paget's disease and bisphosphonates. N Engl J Med 2005; 353: 2616-8.
37. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047-53.
38. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006; 14: 408-18.
39. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006; 38: 617-27.
40. Wright JE, Zhao L, Choi P, Uludag H. Simulating hydroxyapatite binding of bone-seeking bisphosphonates. Adv Exp Med Biol 2004; 553: 139-48.
41. Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002; 8: 1929-44.
42. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 2000; 42: 175-95.
43. Cohen SB. An update on bisphosphonates. Curr Rheumatol Rep 2004; 6: 59-65.
44. Fleisch H. Bisphosphonates: mechanisms of action and clinical use in osteoporosis-an update. Horm Metab Res 1997; 29: 145-50.
45. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12: 6222s-6230s.
46. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 2003; 1: 45-52.
47. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci 2006; 100: 189-94.
48. Frith JC, Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003; 18: 204-12.
49. Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006; 6: 307-12.
50. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103: 7829-34.
51. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006; 21: 684-94.
52. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus 2005; 14: 773-9.
53. Omoigui S. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses 2005; 65: 559-69.
54. Hirano K. Effects of bisphosphonate on the inflammation. Clin Calcium 2003; 13: 128-33.
55. Giuliani N, Pedrazzoni M, Passeri G, Girasole G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand J Rheumatol 1998; 27: 38-41.
56. Olmos JM, De Vega T, Perera L, Riancho JA, Amado JA, Gonzalez-Macias J. Etidronate inhibits the production of IL-6 by osteoblast-like cells. Methods Find Exp Clin Pharmacol 1999; 21: 519-22.
57. Ketteler M, Giachelli C. Novel insights into vascular calcification. Kidney Int Suppl 2006; 105: S5-9.
58. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-59.
59. Dellegrottaglie S, Sanz J, Rajagopalan S. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med 2006; 6: 515-24.
60. Ylitalo R, Monkkonen J, Urtti A, Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 1996; 127: 200-6.
61. Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 2001; 12: 555-60.
62. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels? Kidney Int 2006; 70: 1537-8.
63. Ono K, Wada S. Regulation of calcification by bisphosphonates. Clin Calcium 2004; 14: 60-3.
64. Tuominen OM, Hollmen M, Jaakkola O, Monkkonen J, Ylitalo R. Suppression of viability and acetyl-LDL metabolism in RAW 264 macrophage-like and smooth muscle cells by bisphosphonates in vitro. Methods Find Exp Clin Pharmacol 2002; 24: 487-92.
65. Ylitalo R, Monkkonen J, Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life Sci 1998; 62: 413-22.
66. Ylitalo R, Monkkonen J, Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life Sci 1998; 62: 413-22.
67. Ciosek CP Jr, Magnin DR, Harrity TW, Logan JV, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, et al. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 1993; 268: 24832-7.
68. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992; 33: 1657-63.
69. Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 2003; 32: 15-9.
70. Ylitalo R, Kalliovalkama J, Wu X, Kankaanranta H, Salenius JP, Sisto T, Lahteenmaki T, Ylitalo P, Porsti I. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 1998; 83: 125-31.
71. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 2000; 85: 2793-6.
72. Koshiyama H. Antiatherogenic actions of etidronate on atherosclerosis. Clin Calcium 2002; 12: 378-82.
73. Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2005; 16: 184-90.
74. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000; 15: 599-604.
75. Calabro P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20: 541-6.
76. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000; 23 (Suppl 2): B72-8.
77. Waldman A, Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003; 63: 139-52.
78. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003; 5: 372-8.
79. Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005; 6: 301-23.
80. Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs (review). Int J Oncol 2005; 27: 1401-9.
81. Ii M, Losordo DW. Statins and the endothelium. Vascul Pharmacol 2007; 46: 1-9.
82. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 2004; 35(11 Suppl 1): 2708-11.
83. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
84. Perticone F, Ceravolo R, Maio R, Cloro C, Candigliota M, Scozzafava A, Mongiardo A, Mastroroberto P, Chello M, Mattioli PL. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000; 152: 511-8.
85. Sessa WC. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends Mol Med 2001; 7: 189-91.
86. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
87. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
88. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
89. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8.
90. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
91. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
92. Muniyappa R, Xu R, Ram JL, Sowers JR. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2000; 278: H1762-8.
93. Wei CY, Huang KC, Chou YH, Hsieh PF, Lin KH, Lin WW. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta-and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol 2006; 69: 960-7.
94. Park JK, Muller DN, Mervaala EM, Dechend R, Fiebeler A, Schmidt F, Bieringer M, Schafer O, Lindschau C, Schneider W, Ganten D, Luft FC, Haller H. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterollowering effects. Kidney Int 2000; 58: 1420-30.
95. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616-22.
96. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
97. Mraiche F, Cena J, Das D, Vollrath B. Effects of statins on vascular function of endothelin-1. Br J Pharmacol 2005; 144: 715-26.
98. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
99. Egashira K, Ni W, Inoue S, Kataoka C, Kitamoto S, Koyanagi M, Takeshita A. Pravastatin attenuates cardiovascular inflammatory and proliferative changes in a rat model of chronic inhibition of nitric oxide synthesis by its cholesterol-lowering independent actions. Hypertens Res 2000; 23: 353-8.
100. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol 1999; 19: 2894-900.
101. Meyer-Sabellek W, Brasch H. Atherosclerosis, inflammation, leukocyte function and the effect of statins. J Hypertens 2006; 24: 2349-51.
102. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N, Guglielmotti A, Albani D, Bruno A, Fruscella P, Salmona M, Vecchi A, Pinza M, Mantovani A. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095-100.
103. Nishibori M, Takahashi HK, Mori S. The regulation of ICAM-1 and LFA-1 interaction by autacoids and statins: a novel strategy for controlling inflammation and immune responses. J Pharmacol Sci 2003; 92: 7-12.
104. Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7.
105. Murphy RT, Foley JB, Mulvihill N, Crean P, Walsh MJ. Impact of preexisting statin use on adhesion molecule expression in patients presenting with acute coronary syndromes. Am J Cardiol 2001; 87: 446-8, A6.
106. Ando H, Takamura T, Ota T, Nagai Y, Kobayashi K. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294: 1043-6.
107. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H, Holschermann H. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003; 41: 397-401.
108. Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001; 24: 588-97.
109. Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13: 95-100.
110. Nash DT. Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. J Natl Med Assoc 2005; 97: 1600-7.
111. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9.
112. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-9.
113. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-41.
114. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 2000; 271: 688-92.
115. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001; 280: 874-7.
116. Phillips BW, Belmonte N, Vernochet C, Ailhaud G, Dani C. Compactin enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res Commun 2001; 284: 478-84.
117. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 2001; 69: 299-304.
118. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001; 21: 1636-41.
119. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001; 287: 337-42.
120. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMGCoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
121. Viereck V, Grundker C, Blaschke S, Frosch KH, Schoppet M, Emons G, Hofbauer LC. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem 2005; 96: 1244-53.
122. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-6.
123. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-10.
124. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355: 2185-8.
125. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285: 1850-5.
126. La Croix AZ, Cauley JA, Jackson R. Does statin use reduce risk of fracture in postmenopausal women? J Bone Min Res 2000; 15: S155.
127. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Statin use, bone mineral density and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162: 537-40.
128. Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study group. JAMA 2000; 284: 1921-2.
129. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term intervention with pravastatin in ischaemic disease. Lancet 2001; 357: 509-12.
130. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 2001; 86: 4556-9.
131. Bjarnason NH, Riis BJ, Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 2001; 12: 380-4.
132. Stein EA, Farnier M, Waldstreicher J, Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis 2001; 11: 84-7.
133. Hsia J, Morse M, Levin V. Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose ranging trial. BMC Musculoskelet Disord 2002; 3: 7.
134. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 2007; 40: 1581-7.
135. Tanriverdi HA, Barut A, Sarikaya S. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005; 120: 63-8.